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In ECL cell tumors developed in the setting of hypergastrinemic conditions
(ECLcell carcinoids type 1 and 2), hypergastrinemia is the dominant agent acting
as a promoter in all steps (hyperplasia-dysplasia-neoplasia) of the tumorigenic
sequence. In contrast, it apparently lacks transforming properties as shown by
the absence of ECL cell carcinoids in patients exposed to hypergastrinemia
alone, i.e., those with sporadic Zollinger-Ellison syndrome. The potential trans-
forming factors include: the allelic loss of the MEN-1 suppressor gene in the
genetically predisposed MEN-l patients, an alteration that may induce ECLcell
tumors even in the absence of hypergastrinemia; the still unknown factor(s)
associated with atrophic corporal gastritis; agents whose role in the induction of
human ECL cell tumors is still unclarified, such as basic Fibroblast Growth
Factor, human Chorionic Gonadotropin-a and Transforming Growth Factor-a;
and agents having a favoring role on the ECL exposure to mitogens such as
BCL-2. No information is currently available on the pathogenesis of gastrin-
independent, sporadic ECLcell carcinoids (type 3) or ofgastric neuroendocrine
carcinomas.
INTRODUCTION
According to their more recent classification [1-3] human ECL cell tumors (or carci-
noids) are subdivided into three types: 1) associated with atrophic corporal gastritis (ACG)b;
2) associated with multiple endocrine neoplasia type 1 (MEN-1) and, usually, Zollinger-
Ellison syndrome (ZES); and 3) also defined as sporadic, not associated with any significant
gastric or endocrinological disease. In addition, ECL cells may also be involved in the
development ofpoorly differentiated neuroendocrine carcinomas, at least in those tumors
retaining some characteristics ofcell differentiation.
The mechanisms governing the induction oftype 3, sporadic ECL cell carcinoids and
ofgastric neuroendocrine carcinomas are almost completely ignored. In these neoplasms
the usual presentation as single tumors, the absence of a background of diffuse hyper-
plastic and/or dysplastic proliferation ofextratumoral ECL cells and the frequent finding
ofendocrine cell proliferation in the glandular neckepithelium contiguous with the tumor
[4] indicate afocal carcinogenetic event in the renewal zone ofthe oxyntic glands induced
by factor(s) still unknown.
This is not the case fortype 1 and 2 ECLcell carcinoids. These tumors are often multiple
and represent the ultimate event of a widespread proliferation of ECLcells in the oxyntic
mucosa [5, 6], features that are consistent with a genetic and/or blood-born nature of the
involved oncogenic factors. The occurrence ofdiffuse precursor lesions and the easy access
to their appropriate investigation providedby endoscopic gastric biopsies together with the
availability ofseveral experimental models [7, 8] allowed for a substantial progress in our
aTo whom all correspondence should be addressed: Cesare Bordi, M.D., Istituto di Anatomia
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bAbbreviations: ACG, atrophic corporal gastritis; MEN-1, multiple endocrine neoplasia type 1; ZES,
Zollinger-Ellison syndrome; LOH, loss of heterozygosity; hCG-a, alpha subunit of human chori-
onic gonadotropin; bFGF, basic fibroblast growth factor; TGF-a, transforming growth factor-alpha.
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understanding ofthe mechanisms involved in the development ofthese types ofECLcell
neoplasms inhumans. This review, therefore, is restricted to type 1 and 2 ECLcell carcinoids
and intends to examine the specific factors having a potential role in tumor induction.
HYPERGASTRINEMIA
The potent trophic action ofgastrin on the ECL cell is long known [9]. On this basis,
hypergastrinemia is the first and most widely recognized factor involved in ECL cell
growths ofhypergastrinemic patients [5, 6, 10-12]. Thus, the so-called "gastrin concept",
formulated to explain the mechanism linking pharmacological inhibition ofacid secretion
and ECL cell tumor induction in rodents [7], may well be adapted to man. In hypergas-
trinemic conditions, ECLcell carcinoids develop through a sequence hyperplasia-dysplasia-
neoplasia which has been characterized from the histopathological point of view [13]. A
threshold value ofcirculating gastrin is apparently necessary for evoking ECL cell prolif-
eration whereas ECL cell carcinoid tumors do not develop unless gastrin levels exceed
400 ng/L [6, 14]. Decrease and/or normalization ofhypergastrinemia by either antrectomy
or octreotide treatment induce regression of proliferating ECL cells (Table 1) [15-17]
including carcinoid tumors [18]. However, whereas antrectomy specifically inhibits ECL
cells, octreotide has a more diffuse inhibitory effect also involving the other types of
oxyntic endocrine cells [17].
It is worth noting that among the three main human hypergastrinemic conditions,
ACG, MEN-1/ZES, and sporadic ZES, ECL cell carcinoids develop only in the first two.
In contrast and with two possible exceptions [19, 20], the gastrin-dependent proliferation of
ECL cells does not extend beyond hyperplastic lesions, mostly ofthe simple and/or linear
types [13], in sporadic ZES, an appropriate model for investigating exposure of human
ECL cells to hypergastrinemia alone [6]. From this observation it may be inferred that in
humans hypergastrinemia acts as an effective promoter for ECL cell proliferation but is
unable to induce the transformation of hyperplastic changes of ECL cells into carcinoid
tumors. Additional factors associated withACG or MEN-I (see below) are therefore neces-
sary for such progression. The promoting action ofhypergastrinemia, however, persists in
established ECL cell tumors as shown by tumor regression after antrectomy [18, 21].
Table 1. Effect of six months' treatment with octreotide (500 pg/d) on fasting gastrin and on
chromogranin A (CgA) and human chorionic gonadotropin-a (hCG-a) immunoreactive cells
ofthe gastric body mucosa (mostly ECLcells) in eight patients with corporal atrophic gastritis
(modified from Ferraro et al., 1996).
Before After Difference
treatment treatment (percent) P value
Fasting gastrin (ng/L) 950 238 -74.9 0.01
(250-1800) (10-825)
CgA immunoreactive cells 3.70 2.10 -43 0.0131
Volume density (%)* (1.82-11.24) (1.04-5.10)
hCG-a immunoreactive cells 0.78 0.12 -85 0.0007
Volume density (%)* (0-2.23) (0-0.41)
*The reference volume is the mucosal epithelial component.
Values are expressed as median (ranges).
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ATROPHIC CORPORAL GASTRITIS (ACG)
ACG is the pathological condition showing the highest frequency ofECLcell carcinoids
(type 1) in humans. With one possible exception [22], hypergastrinemia is a consistent
feature of all cases of ACG-associated gastric carcinoids. The transforming mechanism
involved in ECL cell carcinoid induction inACG patients is unknown. Either achlorhydria
and related bacterial and/or chemical perturbations ofthe intragastric environment, or the
altered, largely metaplastic mucosal background have been considered [6, 11, 23].
The typeofACG associated with ECLcell carcinoids is generally regarded to correspond
to the autoimmune variety, associated with pernicious anemia and restricted to the acid-
secreting mucosa, formerly labeled as typeA [1, 12, 14, 24]. However, ECLcell carcinoids
are increasingly detected also in patients with the multifocal type ofACG, largely caused
by Helicobacter pylori infection, and recognizable at the histological levels mostly
because ofthe persistence ofclusters ofoxyntic glands containing parietal cells [23]. The
actual incidence ofthe different types ofACG associated with ECL cell carcinoids, how-
ever, has not been investigated yet.
MULTIPLE ENDOCRINE CELL NEOPLASIA TYPE 1
The suppressor gene responsible for the MEN-I syndrome has been located on chro-
mosome 11, band ql3 [25, 26]. Although the gene has not been cloned and sequenced yet,
the analysis ofnumerous available genetic markers tightly linked to the MEN-I locus with
therecentPCR-microsatellite techniques allows identification ofallelic loss (loss ofhetero-
zygosity, LOH) involving the MEN-I gene [26]. According to the two hit theory, affected
members ofthe MEN-I kindreds have inherited the germline genetic defect in the MEN-I
gene whereas the somatic inactivation of the remaining allele by LOH is the causative
event for the development of tumors in the involved endocrine glands. Indeed, LOH at
11q13 was found in MEN-I tumors ofpancreatic islets [25], parathyroids [27] andpituitary
(for a recent review see [26]).
ECL cell carcinoids associated with the MEN-I syndrome (type 2) almost exclusively
develop in those MEN-I patients also having ZES. LOH at the MEN-I gene locus was
investigated so far in two ofthese patients and documented in both [28, 29] (Figure 1). As
already mentioned, the genetic defect appears to be crucial for the progression of the
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Figure 1. Representative microsatelhte-PCR analysis in gastric ECL cell carcinoids (a) and
neuroendocrine carcinomas (b) of two MEN-1 patients, with or without ZES, respectively.
Analyzed genetic markers tightly linked to the MEN-I locus are reported below each autoradi-
ogram. Arrows indicate allelic loss in tumor DNA (lane T) in comparison to constitutive DNA(lane
C). (Modified from Ref. [29]).
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hyperplastic ECL cell proliferations driven by hypergastrinemia to carcinoid tumors.
Whether it might have an independent role in tumor induction, however, cannot be ascer-
tained in hypergastrinemic patients with ZES.
Although a sporadic observation of ECL cell hyperplasia in a MEN-1 patient with
negligible elevation ofserum gastrin was previously reported [6], the clue is likely provided
by a recently observed case [29]. This was a female patient with a familial history of
MEN-I but no ZES, no personal history ofZES related symptoms including normal circu-
lating levels of gastrin and absence of gastrinomas or of gastric mucosal hypertrophy at
autopsy. Moreover she presented hyperparathyroidism, Cushing's syndrome and multiple
islet cell adenomas. At the gastric level multiple tumors immunohistochemically reactive
for chromogranin Abut unreactive for somatostatin, gastrin, and serotonin were found in
oxyntic mucosa of the stomach. They included multiple benign carcinoids (Figure 2a,b)
varying in size from 0.5 to 1.5 cm. and two independent, intermediate cell neuroendocrine
carcinomas (Figure 2c), which metastatized to gastric lymph nodes and liver. Proliferation
of extratumoral oxyntic endocrine cells was not seen except for a mild degree of simple
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Figure 2. Gastric neuroendocrine tumorsin apatient withMEN-1 syndrome but withouthyper-
gastrinemia. a) One ofmultiple carcinoids located inthe mucosa and submucosa (Hematoxylin-eosin,
x 75). b) Sevier-Munger argyrophil reaction in the cells of a carcinoid (x 200). c) Neuroendocrine
carcinoma composed of solid clusters of intermediate size cells with extensive central necrosis.
Heterogeneous distribution ofchromograninAimmunostaining with abundance ofimmunoreactive
cells in the lower half of the picture (Immunoperoxidase with hematoxylin counterstaining, x 75).
d) Ultrastructure of the neuroendocrine carcinoma showing secretory granules with small, dense,
eccentric cores surrounded by a less dense halo (arrows). Bar is equal to 1 ,um. (x 13,600).
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hyperplasia. LOH at llql3 region was found in the neuroendocrine carcinomas (Figure 1)
that ultrastructurally revealed heterogeneous cell content of granules, characterized by a
small, dense and eccentric core, a less dense halo and a wavy limiting membrane (Figure
2d). This granule morphology was consistent with that ofmodified ECLcells but not with
that of any other type of gastric endocrine cells. LOH and ultrastructure could not be
investigated in benign carcinoids.
From this observation itcan be concluded that multiple gastric endocrine tumors with
all evidence composed ofECLcells may develop in MEN-I patients by LOH atllql3 even
in the absence of the promoting stimulus of hypergastrinemia, indicating that the genetic
defect per se may be an adequate oncogenic factor for ECL cells.
FEMALE GENDER
A favoring role ofthe female gender in gastrin-dependent growths ofthe ECL cells is
supported by several lines of evidence. In ZES, either sporadic or associated with MEN-1
syndrome, ECL cell density was found to be higher in women than in men [30, 31]. In
addition, women do not present the decrease in ECLcell density with age seen in old men,
a finding presented not only by ZES patients [31] but also by normal subjects [32]. Severe
hyperplasia ofECLcells ofpatients withACG andhypergastrinemia is by farmore frequent
in females than in males [33]. In this condition, ECL cell carcinoids occur in female
patients in two thirds ofcases whereas 80% ofgastrin independent ECLcell tumors ofthe
sporadic variety (type 3) occur in male patients [1]. These observations are in agreement with
the results ofexperiments in rats withpharmacologically inducedhypergastrinemia in which
ECLcell carcinoids developed with muchhigherfrequency infemale than in male rats [34].
The mechanism that potentiates the trophic effect ofgastrin on ECLcells in the female
sex is still unclarified. In this regard, it may be relevant the observation ofafemale patient
with ZES and breast cancer, in which an unusually florid evolution of a formerly mild
ECL cell hyperplasia abruptly appeared after withdrawal of long-standing anti-estrogen
therapy accompanied by increase in circulating levels of 17,-estradiol andprogesterone [35].
BCL-2
BCL-2, a protein encoded by the proto-oncogene bcl-2, enhances cell survival by
blocking programmed cell death (apoptosis) [36]. Several types of glandular epithelial
cells undergoing hyperplasia and apoptotic mediated involution in response to hormonal
stimuli express this protein [37]. Activation of the bcl-2 oncogene and related BCL-2
overexpression have been documented in a variety ofhuman tumors originating from dif-
ferent, embryologically unrelated tissues [38, 39]. They contribute to tumor induction and
progression by extending cell survival and, therefore, cell exposure to oncogenic factors
without affecting the cell proliferation rate.
In our laboratory BCL-2 was found to be consistently expressed by a subset ofendo-
crine cells preferentially located in the intermediate region of the normal human oxyntic
glands [40]. This distribution suggests a role in prolonging cell survival during the physio-
logical process of downward migration of these cells. BCL-2 was also commonly
expressed in hyperplastic endocrine cells of hypergastrinemic patients that are mostly
composed ofECL cells (Figure 3) [6, 24]. Hence, it was argued that the ECL cell is largely
involved in such expression and in the related apoptotic regulated mechanism(s).
However, BCL-2 immunoreactivity of ECL cells was found to substantially diverge
in hypergastrinemic conditions with different risk of ECL cell carcinoid development
(Table 2). In comparison with normal subjects, in fact, the fraction of oxyntic endocrine
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Figure 3. Immunohistochemical expression of BCL-2 by hyperplastic ECL cells in a patient
with atrophic gastritis. Stromal lymphocytes also are strongly immunoreactive (arrows).
(Immunoperoxidase, x 110).
cells expressing BCL-2 was significantly lower in cases of sporadic ZES (with low or no
carcinoid risk), unchanged in cases of ZES/MEN-1 (of intermediate carcinoid risk) and
significantly increased in cases ofACG (with the highest incidence ofcarcinoid development)
[40]. In contrast, in established ECLcell carcinoids the expression ofBCL-2 appeared to be
erratic and in most cases weak or absent even in the presence of strong immunoreactivity
of extratumoral, hyperplastic ECL cells. The major role of BCL-2, therefore, seems to be
in the early stages of the ECL cell tumorigenic sequence in analogy with similar findings
presented by non endocrine gastrointestinal adenocarcinoma [41-43].
Table 2. Ratio ofBCL-2 immunoreative cells to chromogranin A (CgA) immunoreactive cells
in the oxyntic mucosa of normal subjects and ofpatients with different conditions associated
with hyperplasia ofECL cells (modified fromAzzoni et al., 1996).
BCL-2/CgA
Fasting immunoactive
Patients gastrin cells
n age (ngAL) (percent)
Normal serum gastrin and 10 39 <100 50.0
oxyntic mucosa (16-81) (24.6-74.0)
Zollinger-Ellison syndrome, sporadic 9 52 1900 4.6*
(35-61) (470-29,450) (0.9-42.0)
Zollinger-Ellison syndrome and 4 50 570 55.6
multiple endocrine neoplasia Type 1 (30-61) (560-1000) (29.4-83.8)
Corporal atrophic gastritis 9 50 520 87.6t
(22-70) (58-1150) (12.1-199.4)
Data are expressed as median (ranges).
*Difference from normal: p<0.001.
tDifference from normal: p<0.006.
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The discordant results obtained in different pathological conditions having comparable
hypergastrinemic levels indicate that the abnormal regulation of the bcl-2 gene in hyper-
plastic ECL cells is independent ofthe influence ofgastrin. Indeed, the heaviest degree of
BCL-2 expression was found in a very unusual case of severe oxyntic endocrine cell
hyperplasia associated with ACG and normal serum levels of gastrin [40]. Nevertheless,
our observations may fit with the results ofexperiments with 3H-thymidine incorporation
in pharmacologically induced hypergastrinemia ofthe rat [44]. These experiments showed
that the ECL cell labeling index presented a transient peak elevation during the first two
weeks of exposure to hypergastrinemia followed by decline and return to control levels at
10 weeks, in spite ofpersistent hyperplasia ofECL cells. It was suggested, therefore, that
BCL-2 overexpression may represent the mechanism that replaces the early, gastrin
dependent peak of mitotic proliferation and extends the life span offormerly proliferated
ECL cells [40], thus allowing forthe accumulation ofgenetic andenvironmental influences
necessary for tumor induction.
An interesting, though unexplained finding in both hyperplastic and tumoral ECL
cells was the frequent reverse expression of BCL-2 and of the neuroendocrine granule
marker chromogranin A [40].
ALPHA SUBUNIT OF HUMAN CHORIONIC GONADOTROPIN (hCG-oc)
hCG-x is a protein of unknown functional significance whose expression has been
regarded as a marker of malignancy in pancreatic endocrine tumors [45]. It may also be
expressed by all other types of endocrine tumors occurring in MEN-1 syndrome [26],
although in this case it usually does not carry adverse prognostic significance.
In ECL cells ofnormogastrinemic subjects hCG-oc is usually undetectable. In contrast,
it is distinctively and characteristically expressed by ECLcells ofhypergastrinemic patients
[11, 24, 46]. The volume density of hCG-a immunoreactive cells in the oxyntic mucosa
of such patients correlates directly with the degree of their hypergastrinemia (Figure 4a),
and the cell content of the protein can be decreased by pharmacological suppression of
hypergastrinemia (Table 1) [15, 16]. The more pronounced hCG-a expression is usually
observed in ECL cells forming hyperplastic micronodules whereas significantly fewer
immunoreactive cells are commonly found in carcinoid tumors [4]. This observation indicates
that the gastrin dependent appearance ofthis novel protein has implications for the induction
ofECLcell carcinoids rather than for theirprogression. WhenhCG-at is heavily expressed
by tumoral ECL cells (Figure 4b), however, it may be associated with unfavorable tumor
evolution similar to that found in pancreatic endocrine tumors [29].
BASIC FIBROBLAST GROWTH FACTOR (bFGF)
bFGF controls cell proliferation and differentiation in many organs and tissues, mostly
but not exclusively of mesodermal origin. This protein is known to be abnormally elevated
in MEN-1 syndrome [47] and largely contributes to the circulating parathyroid mitogen
factor that characterizes MEN-I patients [48].
Using immunohistochemistry and Northern analysis we demonstrated that bFGF is
expressed by a subset of unidentified normal oxyntic endocrine cells and by proliferating
ECL cells of hypergastrinemic patients including both hyperplastic lesions and carcinoid
tumors [49]. The ECL cells, therefore, may represent a potential source of the parathyroid
mitogenic factor in patients with MEN-1 syndrome. Indeed, we have found the highest
degree ofbFGF expression in hyperplastic ECL cells of a MEN-I patient showing multiple
metastatizing ECL cell carcinoid (Figure 5) [29].
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Figure 4. Alpha-subunit of human chorionic gonadotropin (hCG-a) in ECL cells exposed to
hypergastrinemia. a) Correlation between plasma gastrin levels and volume density of hCG-a
expressing cells [15]. b) Unusual pronounced immunoreactivity in an ECLcell carcinoid ofahyper-
gastrinemic MEN-1 patient who died of metastatic tumor disease in the liver (Immunoperoxidase
without counterstaining, x 130).
Whether bFGF production by ECL cells may have some autocrine influences on the
induction ofECLcell carcinoids remains to be elucidated. It has been suggested that locally
released bFGF, a potent mitogen for smooth muscle cells, may represent the growth factor
responsible for the pronounced stromal proliferation of smooth muscle cells originating
from the muscularis mucosae that is frequently associated with ECLcell micronodules or
carcinoid tumors [50].
Figure 5. Heavyimmunoreactivity forbasic fibroblast growth factor in hyperplastic ECLcells
of a MEN-1 patient (arrows). Carcinoid tumor cells (on the right) display a lower degree of
immunostaining. (Immunoperoxidase, x 70).
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Figure 6. Outline ofthe mechanism involved in the induction ofgastrin-dependent ECL cell
carcinoids.
INSIGHTS FROM EXPERIMENTAL MODELS
Several experimental models of ECL cell tumors have been proposed (for a recent
review see [14]). Of them the ECL-omas of the rodent Mastomys appear to be the most
promising one since it may reflect either the genetic mechanism, when spontaneously
developing innormogastrinemic old animals, orthe gastrin dependent mechanismin animals
made hypergastrinemic by pharmacological treatment with the irreversible H2 blocker
loxtidine that results in a significantly accelerated tumor formation [14]. During the
hypergastrinemia driven induction ofMastomys ECL-omas, increased ECLcell content of
the mitogenic agent transforming growth factor-a (TGF-a) and ofits specific EGF receptor
have been documented. Accordingly, the hypothesis has been formulated that gastrin-
dependent TGF-a production and related autocrine stimulation may be responsible for a
gastrin-independent phase ofECLcellproliferation [14]. TGF-a production by human ECL
cells has not been documented so far.
CONCLUSIONS
The clinical and pathological evidence indicates that in hypergastrinemic patients
gastrin is the dominant agent responsible for ECL cell proliferation at all steps of the
sequence hyperplasia-dysplasia-neoplasia. Hypergastrinemia appears to behave as apromoter
but apparently lacks transforming properties as shown by the absence of ECL cell carci-
noids in patients exposed to hypergastrinemia alone, i.e. those with sporadic ZES. On the
basis of the available knowledge the potential transforming factors responsible for the
development of gastrin-dependent ECL cell carcinoids (type 1 and 2) may be subdivided
into: 1) factorwith proven oncogenic activity such as the allelic loss oftheMEN-I suppressor
gene in the genetically predisposed MEN-I patients, an alteration that may induce ECL
cell tumors even in the absence of hypergastrinemia; 2) factor(s) still unknown such as
those associated with ACG; 3) agents whose role in the induction of human ECL cell
tumors is still unclarified, such as bFGF, hCG-a andTGF-a; and4) agents having afavoring
role on the ECLexposure to mitogens such as BCL-2.Aschematical outline ofthe process
ofECL cell tumorigenesis in hypergastrinemic states is shown in Figure 6.
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